NSRX is trading 8% up at $3.29 in pre-market, suggesting a technical rebound after recent weakness as no company-specific catalysts were identified.
- The stock previously dropped 11.2% to $3.05 on July 7, 2026, amid a lack of fundamental news.
- There are no fresh news releases, SEC filings, earnings, or major analyst actions dated July 8, 2026, linked to Nasus Pharma.